contact us jpkrencn

事業内容

Inhalation Formulation R&D Platform

あなたはここにいる:ホーム > 事業内容 > Integrated Projects > Inhalation Formulati...

Medicilon is familiar with the development process and has extensive R&D experience of various inhalation formulations, especially in the field of DPI, nebulizer and nasal spray. The R&D are fully integrated with the requirements of domestic and foreign policies, regulations and guidelines.

Under the new pharmaceutical policy, pharmaceutical companies have become more enthusiastic about the research and development of formulation technology. Among them, inhalation formulations have received close attention as an important part of high-end formulations. At the same time, as air pollution and the aging of the population intensify, causing increased occurance of respiratory diseases, more companies have begun to coordinate the layout of inhalation formulation and nasal sprays, including asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis and other therapeutic areas. Such formulations could be quickly absorbed, reduce the dosage and reduce adverse drug reactions. The inhalation formulations are used in innovative drugs, improved new drugs and generic drugs.

Inhalation formulations include dry powder inhaler (DPI), nebulizer, and Metered Dose Inhaler (MDI).

  • DPI
  • Dry Powder Inhaler (DPI) refers to the formulation of solid micronized raw material medication alone or mixed with a suitable carrier, using a special dry powder inhalation device for the patient to inhale the aerosolized medicine to the lungs.

  • Nebulizer
  • Nebulizer refers to a drug delivery device to administer medication in the form of a mist inhaled into the lungs.

  • MDI
  • A Metered Dose Inhaler (MDI) is a device that delivers a specific amount of medication to the lungs, in the form of burst of aerosolized medicine that is usually self-administered by the patient via inhalation.

Inhalation formulations are unique in terms of technology development, review and approval. It is necessary to comprehensively consider the technology, quality control, drug delivery device and production of the final product. Medicilon is familiar with the development process and has extensive R&D experience of various inhalation formulations, especially in the field of DPI, nebulizer and nasal spray. The R&D are fully integrated with the requirements of domestic and foreign policies, regulations and guidelines.

In addition to the conventional physical and chemicalproperties , the quality of inhaled formulations also includes some special indicatiors such as Aerodynamic Particle Size Distribution (APSD), Fine Particle Dose (FPD), Delivered-Dose Uniformity (DDU) and Delivery Rate and Total Delivered. These studies require the use of proprietary analytical equipment. Medicilon equips with the New Generation Impactor and BRS 2100 Breath Simulator from Copley Scientific and Particle Size Analyzer from Sympatec. The equipped state-of-the-art equipment could fulfill the quality research and in vitro evaluation of various inhalation formulations.

Medicilon's inhalation formulation R&D platform welcomes any inquiries from pharmaceutical companies and collabrates with Medicilon to complete the research and development of inhalation formulations.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. Medicilon grows together with the clients and delivers the new drug research and development services to more than 700 clients globally. Medicilon is proud to contribute to human health in the globe.

関連研究室